The design of guide RNAs (gRNAs) is critical for the efficacy and safety of CRISPR-based gene editing therapeutics; however, suboptimal gRNA design can lead to unintended insertions or deletions (Indels) and unexpected genotoxic effects. As the field advances towards editing multiple gene targets across diverse cell types, there is an increasing need to optimize and de-risk gRNA design.

Cassidy Bio provides an AI-driven platform that accelerates and optimizes therapeutic research and development in gene editing. The company's tailored predictive platform and data optimize guide RNA design, predict on/off-target effects, and streamline decision-making across the therapeutic development lifecycle. Cassidy Bio applies AI-driven predictive tools alongside advanced wet lab capabilities to accelerate, optimize, and de-risk the development of next-generation gene-editing therapies. The company is building a comprehensive predictive platform based on large language models (LLM) for gRNA design, powered by proprietary, clinically relevant genomic data generation, state-of-the-art predictive algorithms, and rigorous wet lab validation.

Predictive platform for gRNA design using large language models (LLM)

Rapid gRNA ranking, including on/off-target predictions

Comprehensive on/off-target predictions across all potential guides, multiple editing technologies, and diverse cell types

Identification of both high- and low-frequency off-targets with a full genotoxicity profile spanning tens of thousands of genomic variants

Proprietary, clinically relevant genomic data generation

State-of-the-art predictive algorithms

Rigorous wet lab validation

Cassidy Bio's primary customers are research teams involved in therapeutic research and development in gene editing.